Objective: This study was conducted to characterize the coordinated molecular changes evoked in the structure and composition of the wall of a venous segment when exposed to fistula flow. Methods: An arteriovenous shunt was created in adult C57BL/6J mice. Remodeled veins and contralateral control jugular veins were isolated 7 days after surgery. Total RNA was isolated, linearly amplified, and the transcriptional profiles of this early adaptive response were obtained by microarray analysis. Histologic and immunohistochemical analyses were performed on remodeled veins and control veins isolated on days 1, 3, 5, and 7 after surgery to further examine distinct spatial and temporal aspects of this early process. Results: There were 131 significantly upregulated and 165 downregulated genes in the remodeled vein compared with the control jugular vein. Genes involved in extracellular matrix reorganization were highly upregulated. Movat's pentachrome staining revealed ground substance on day 3 that was not observed on day 5. The appearance of elastin fibers was first observed on day 7. Morphometric analysis demonstrated maximum wall thickness on day 3. Immunohistochemical analysis revealed the presence of tenascin-C, thrombospondin, lysyl oxidase, and osteopontin in different cell types at different time points throughout the first week after surgery. Surg 2006;44:863-70.) Clinical Relevance: The Kidney Dialysis Outcomes Quality Initiative has proposed the construction of arteriovenous fistulas as the primary vascular access for hemodialysis. As the vein is exposed to arterial flow, the vein wall dilates and a vascular remodeling process is triggered. With continued exposure, intimal hyperplasia occurs at the anastomosis that in many cases leads to failure. However, the molecular mechanisms by which the outflow vein remodels into a mature fistula remain incompletely understood. By investigating venous remodeling in a fistula model, candidate genes important for the remodeling process are discovered and their functional significance examined. Thus, the identification of relevant genes involved in this process should provide insight into arteriovenous fistula maturation and may suggest novel approaches for achieving higher patency rates.
Arteriovenous fistulas (AVF) are the best vascular access option for patients with end-stage renal disease on hemodialysis. 1 The ability of the venous outflow tract to mature depends upon on the state and size of the vessels and their ability to adapt to a change in hemodynamic environment. 2, 3 During this adaptive period, the vein wall senses the change in its biomechanical environment, and the process of structural and functional changes in the vascular wall, known as vascular remodeling, is initiated. 4 Vascular smooth muscle cells (VSMC) migrate and proliferate in the intima; and the vessel wall changes in response to the new arterial environment and its associated shear stress, oxygen tension, metabolite concentrations, and pH. 5 The specific mechanisms by which this occurs still remain poorly characterized.
The extracellular matrix (ECM) of a mature vessel consists of collagen, elastin, and ground substance composed of proteoglycans, glycoproteins, and glycosaminoglycans. Proteoglycans bind water to form a gel-like substance. 6 Although vein walls have a thin layer of VSMCs and minimal elastin, arterial walls are composed of alternating lamellae of VSMCs and elastin, providing a crucial support structure that allows it to sustain the hemodynamic pressures present in arterial conduits. 6, 7 During venous remodeling, the vein wall assembles a reinforced scaffolding capable of withstanding the increased hemodynamic force of arterial flow.
Our laboratory previously developed and began to characterize a mouse model of an AVF to investigate the early stages of venous remodeling. 8 In our model, this corresponds with the first 7 days after surgery. Here, we used transcriptional profiling approaches to define the initial molecular changes that occur in the vessel wall during this adaptive period as it responds to a change in its biomechanical environment. We hypothesize that coordinated molecular changes in the structure and composition of the vessel wall are evoked as a vein is exposed to arterial flow.
MATERIALS AND METHODS
Surgical procedure. In this study, we used a mouse model of an AVF with 8-to 10-week-old C57BL/6J male mice that was recently developed in our laboratory 8 in which we observed strong remodeling using this strain and age. We did not observe differences in remodeling between genders. The mice were anesthetized by an intraperitoneal injection of tribromoethanol, 125 to 240 mg/kg (Avertin, Fisher Scientific, Pittsburgh, Penn). A vertical incision was made over the right neck. The external jugular vein was identified, and all branches were ligated and divided using 10-0 nylon (US Surgical, Norwalk, Conn). An arteriovenous shunt was created between the jugular vein and the common carotid artery by using a 2-mm microvascular catheter (Fine Science Tools, Foster City, Calif) and secured with 8-0 silk ties (US Surgical). Clamps were removed and pulsatile flow was observed in the jugular vein. Sham surgery was performed in which all branches of the external jugular vein were ligated and divided using 10-0 nylon (US Surgical), the carotid artery was dissected free from its surrounding tissue, and a 2-mm microvascular catheter was placed next to both the jugular vein and the carotid artery. In all cases, the incision was closed using 5-0 Vicryl suture (US Surgical). Operative time averaged 45 to 60 minutes.
All animal procedures and care were performed with approval from the Institutional Animal Care and Use Committee and complied with the Guide of the Care and Use of Laboratory Animals. 9 Tissue isolation. External jugular vein segments exposed to arterial flow were isolated on days 1, 3, 5, and 7 after surgery. The incision was reopened and the remodeled vein was exposed and dissected free from the surrounding tissue. Patency was confirmed by visualizing pulsatile arterial flow in the vein segment. The contralateral jugular vein was isolated as a control at all time points. The animal was euthanized under anesthesia by cardiac puncture and incision of the left renal vein. Perfusion fixation at 110 mm Hg was performed using phosphate buffered saline (PBS), followed by 2% paraformaldehyde via the left ventricle. A 4-mm segment of remodeled vein was isolated distal to the microvascular catheter. The vessels were oriented and snap frozen in optimal cutting temperature compound for cryosectioning and histologic, and immunohistochemical staining. A 4-mm segment of sham operated jugular vein and carotid artery was also isolated as a control and then snap frozen after perfusion with PBS and 2% paraformaldehyde.
RNA extraction. A 4-mm segment of postoperative day 7 remodeled vein and contralateral control jugular vein were perfused with PBS, isolated, and frozen. To obtain sufficient RNA for microarray analysis, the remodeled vein from five mice were pooled in each experiment (n ϭ 3).
The tissue was pulverized and total RNA was extracted using an RNeasy micro kit (Qiagen, Valencia, Calif). RLT Buffer containing ␤-mercaptoethanol (Qiagen) was added to dissolve the tissue. This mixture was then applied to an RNeasy micro column (Qiagen). The column was washed with RW1, incubated with DNAse, and then serially washed with RW1 and RPE. The RNA was eluted with RNAse-free water.
Linear amplification of complimentary RNA. RNA (500 ng) was used for linear amplification of complimentary RNA (cRNA) based on the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies, Palo Alto, Calif). cDNA was synthesized from the total RNA using the T7 promoter primer, 5x first strand buffer, 0.1M dithiothreitol (DTT), 10mM deoxyribonucleotide triphosphate, Mouse Moloney Leukemia Virus reverse transcriptase, and RNAseOUT. The reaction was incubated at 40°C for 2 hours. Fluorescent complementary RNA (cRNA) was synthesized from the cDNA by using an in vitro transcription master mix consisting of nuclease free water, transcription buffer, DTT, nucleotide triphosphate mix, labeled cytidine 5'-triphosphate, 50% polyethylene glycol, RNAseOUT, inorganic pyrophosphate, and T7 RNA polymerase, and incubated at 40°C for 2 hours. The amplified control jugular vein and remodeled vein cRNAs were labeled with cyanine 3 and cyanine 5, respectively, and then purified using an RNeasy mini column (Qiagen). RNA quality was evaluated using Bioanalyzer 2100 (Agilent Technologies).
Oligonucleotide microarray hybridization. Agilent Oligonucleotide Mouse Developmental 22K microarrays (20,280 genes) were used in these experiments. Two micrograms of labeled cRNA of the jugular vein and remodeled vein was fragmented in fragmentation buffer for 30 minutes at 60°C. Hybridization buffer was added to terminate the fragmentation reaction. The labeled cRNA samples were hybridized to the oligonucleotide Agilent Mouse Developmental 22K microarray slide for 17 hours at 60°C. The slide was serially washed with wash solution 1 and 2. The microarray slides were then scanned using an Agilent scanner. The images from the three independent experiments were quantified by using Agilent Feature Extraction software, and the data were then transferred to Argus, a database designed in our laboratory, to facilitate statistical analysis. 10 Immunohistochemical analysis. Five micrometer sections of the remodeled vein (starting 1 mm distal to the microvascular catheter), contralateral control jugular vein, and sham operated vessels were processed for histology and immunohistochemistry. Slides were stained with a modified Movat's pentachrome for gross morphologic examination. Specimens were fixed with 10% buffered formalin and then sequentially stained with Alcian blue, alkaline alcohol, Verhoeff's hematoxylin, 2% ferric chloride, sodium thiosulfate, crocein scarlet-acid fuchsin, 0.5% acetic acid, 5% phosphotungstic acid, saffronic alcohol, graded alcohol dehydration, and then mounted with Permount (Fisher Scientific).
Frozen sections were fixed with acetone, serially blocked with normal serum and 1% peroxide, and then incubated with primary antibody, followed by secondary antibody conjugated to peroxidase. Slides were then developed using AEC chromogen and counterstained with Gill's Hematoxylin No.1. Sections were analyzed for the presence of lysyl oxidase (rabbit antirat antibody, 1:250, Dr. Herbert Kagan, Boston University School of Medicine, Boston, Mass) and osteopontin (goat antimouse antibody, 1:32, Sigma, St. Louis, Mo). Additional blocking with avidin and biotin was performed before incubating with anti-tenascin-C (rat antimouse antibody, 1:6000, Sigma). Slides were then incubated with secondary biotinylated antibody and then treated with the ABC Elite peroxidase kit (Vector Laboratory, Burlingame, Calif) and developed using AEC chromogen and counterstained.
DAKO Animal Research Kit for Peroxidase (DAKO Cytomation, Carpinteria, Calif) was used to stain sections for anti-thrombospondin (mouse monoclonal antibody to thrombospondin 1 with mild cross-reactivity to thrombospondin 2, 1:20, Lab Vision Corporation, Fremont, Calif). Sections were fixed in acetone, blocked for endogenous peroxidase using 3% peroxide, and then incubated with biotinylated anti-thrombospondin. Slides were then treated with streptavidin-peroxidase, developed with an AEC chromogen, and counterstained. A negative control was performed by substituting an isotype immunoglobulin G antibody.
Morphometry. Morphometric analysis was performed on specimens stained with Movat's pentachrome. Digital images were analyzed using ImageJ 1.34. 11 Wall thickness was measured at 8 points (45°) around the vessel circumference from the endothelium to the tissue edge and then averaged for each sample (n ϭ 4 for each time point). 12 Statistics. Data from the microarray analysis are compared using Z-pool, an intensity-based variance estimation algorithm previously developed in our laboratory. 13 Differences were considered to be significant at P Ͻ .05. Data from the morphometric analysis are expressed as mean Ϯ SD. Comparisons were made using a two-tailed Student's t test. Differences were considered to be significant at P Ͻ .05.
RESULTS

Transcriptional profiling of venous remodeling.
To begin characterizing the early stages of venous remodeling, we performed transcriptional profiling experiments to compare remodeled veins (7 days after surgery) with control jugular veins. Of the 20,280 genes represented in the microarray used in this study, 12,044 and 12,362 genes were expressed at intensities above threshold in the remodeled vein and jugular vein, respectively. There were 131 significantly upregulated and 165 downregulated genes in the remodeled vein compared with the control jugular vein (Fig 1) . Genes upregulated during venous remodeling, when classified by biologic function, fell into three main categories: reorganization of the ECM, chemokine signaling, and platelet-derived growth factor (PDGF) signaling. Tables I and II list the highly upregulated and downregulated genes, respectively, in the remodeled vein compared with the control vein. The entire microarray data organized as a searchable database as well as supplemental methods and figures can be found at http://vessels.bwh.harvard. edu/abeles/1.
Changes in the extracellular matrix during venous remodeling. As several highly regulated genes defined by the transcriptional profiling experiments have a role in ECM remodeling, we first performed experiments to define the gross histologic changes in the extracellular milieu experienced by the vascular wall during venous remodeling. To this end, Movat's pentachrome staining was used to define all elements of connective tissue: nuclei and elastin are stained black, collagen is yellow, muscle is red, and ground substance is blue. When this stain is used, the sham operated carotid artery displays distinct lamellae of VSMCs alternating with elastin and a thin rim of collagen in the adventitia (Fig 2, A) . The wall of the control jugular vein is comprised of one layer of VSMCs, surrounded by collagen and a small amount of ground substance at the tissue edge (Fig 2, B) . On day 1, ground substance is observed along with an increase in vessel wall thickness (Fig 2, C) . The wall thickens as the amount of ground substance increases during days 3 to 5, after which ground substance disappears (Fig 2, D and E) . Additional VSMCs i n t h e subendothelial layer are also visualized on day 5 (Fig 2, E) . By day 7, the wall consists of collagen and subendothelial VSMCs, and no ground substance is observed (Fig 2, F) . Interestingly, at the junction of these two layers, elastin is observed as small black punctuate dots and wisps demonstrating a primitive internal elastic lamina that appears 7 days after the vein is first exposed to arterial flow (Fig 2, F inset) .
Morphometric analysis was used to obtain total wall thickness measurements on days 1, 3, 5, and 7, and in control jugular vein to account for the observed changes in the ECM. Within 24 hours of surgery, the vein wall increased in thickness from 72.06 Ϯ 1.68 m to 151.09 Ϯ 0.84 m. By day 3, wall thickness has reached its maximum at 220.24 Ϯ 11.87 m. The change in wall thickness can be attributed to a greater amount of ground substance that is present in the vessel wall as well as a change in vascular permeability that coincides with an acute inflammatory response (present in our model by day 3). Wall thickness has decreased to 191.78 Ϯ 2.20 m by 5 days after surgery and to 157.16 Ϯ 12.83 m by day 7. The change in wall thickness at each time point was significant when compared with the control (P Ͻ .001) (Fig 2, G ) .
Expression of extracellular matrix proteins during venous remodeling. The transcriptional profile of the remodeled vein revealed significantly upregulated genes involved in the reorganization of the ECM. To confirm these changes, immunohistochemistry was performed using four matrix proteins shown to be highly upregulated in the array experiments (tenascin-C, thrombospondin, lysyl oxidase, and osteopontin) and that have previously been implicated in matrix organization. [14] [15] [16] [17] Tenascin-C, an ECM glycoprotein expressed during remodeling, 18, 19 is not visualized in the control carotid artery or the control jugular vein (Fig 3, A and B) . By day 1, tenascin-C is expressed in subendothelial VSMCs (Fig 3, C) . The expression continues to be observed in these cells and in inflammatory cells within the vessel wall by day 3 (Fig 3, D) . By days 5 and 7, tenascin-C expression is seen throughout the wall of the remodeling vein (Fig 3, E  and F ) .
We next examined the expression of thrombospondin, an adhesion-modulating protein of the ECM. 6 Thrombospondin is not expressed in the carotid artery or control jugular vein (Fig 3, G and H) . By day 1, expression is visualized in infiltrating inflammatory cells (Fig 3, I ) . Thrombospondin continues to be observed in these cells by day 3 (Fig 3, J ) . Five days after surgery, expression is prominent in the endothelium and VSMCs (Fig 3, K ) . By day 7, thrombospondin is seen throughout the wall of the remodeling vein (Fig 3, L ) . Lysyl oxidase, an enzyme that initiates the cross-linking of collagen and elastin fibers, 16 is not expressed in the control carotid artery or jugular vein (Fig 3, M and N ) . By day 1, it is visualized in infiltrating inflammatory cells (Fig 3, O) . The expression of lysyl oxidase is more prominent in these cells and VSMCs on day 3 (Fig 3, P) . Five days after surgery, lysyl oxidase is observed throughout the vessel wall (Fig 3, Q) . This pattern of expression is also seen on day 7 (Fig 3, R) .
Finally, osteopontin, an adhesion modulating protein of the ECM that is also implicated in collagen organization 6, 20 is minimally expressed in the carotid artery and jugular vein (Fig 3, S and T ) . By day 1, it is observed sporadically in the endothelium and in infiltrating inflammatory cells (Fig 3, U ) . Osteopontin is visualized throughout the wall in the endothelium, inflammatory cells, VSMCs, and along the tissue edge 3 days after surgery (Fig 3, V ) . By days 5 and 7, osteopontin is expressed throughout the vessel wall, including the endothelium and VSMCs (Fig 3, W and X ) .
DISCUSSION
AVFs are widely used for vascular access for hemodialysis. The remodeling of the venous outflow tract depends on the ability of the vessel wall to adapt to changes in its biomechanical environment, and this event is critical for i t s patency. 3 Nevertheless, the molecular mechanisms by which the vein remodels remain unknown. Transcriptional profiling can provide new insights into venous remodeling. Kalish et al 21 previously used this technology to identify differentially regulated genes in canine interposition vein grafts Յ30 days of surgery. Here, we have used microarray analysis to identify the transcriptional profile of genes involved in the adaptive response of venous remodeling in our model. The array employed, although representing a large number of genes (20, 280) , was biased toward genes important in development. By utilizing these arrays, we were able to elucidate which genes, of those expressed mainly during murine development, are important for venous remodeling in an adult.
Three main categories of biologically significant genes emerged: chemokine signaling, PDGF signaling, and reorganization of the ECM. Chemokine signaling has been implicated in VSMC migration and proliferation resulting in intimal hyperplasia as a consequence of arterial injury. 22, 23 PDGF signaling has also been implicated in intimal hyperplasia owing to VSMC migration and proliferation in models of arterial injury and venous remodeling. 24, 25 Importantly, Kalish et al 21 demonstrates an upregulation of different collagen types and their precursors during the first 7 days after vein grafting. These observations, together with the data presented in this study, strongly suggest an important role for the ECM during the early stages of venous remodeling.
Changes in the ECM have been previously described in other models of vascular remodeling. 26, 27 These stud-ies have demonstrated that the ECM of a vessel is not a static entity. It is constantly degraded by various gelatinases and collagenases that constitute matrix metalloproteinases (MMPs) and then resynthesized. 28 The ECM consists of collagen, elastin, and a watery, gel-like ground substance. It has been postulated that the ground substance allows the ECM to resist compressive forces. 6 During venous remodeling, VSMCs must separate from their ECM to migrate to the intima and proliferate, creating a neointima. The activation of MMPs is critical in promoting VSMC migration. 29 The expression of adhesion-modulating glycoproteins, such as osteopontin, tenascin-C, and thrombospondin, is induced, and their counter-adhesive properties allow VSMCs to migrate through the vessel wall from the media to the intima. 6, 18, 30 These glycoproteins have also been implicated in matrix organization. 14, 15, 17 By using a modified Movat's pentachrome stain, we were able to delineate all the components of the remodeled vein wall, including changes in the ECM in response to venous remodeling. Furthermore, we demonstrated total wall thickness increases until it reaches a maximum thickness on day 3. This increase in wall thickness coincides with an increased amount of ground substance present. Of interest is that this peak of wall thickness and the magnitude of ground substance also corresponds to the maximum influx of inflammatory cells noted in our past study. 8 A change in vascular permeability, usually associated with an acute inflammatory response, may be reflected in the total wall thickness at early remodeling stages. How the inflammatory response leads to the presence of ground substance and their contribution to venous remodeling remains unknown.
Elastin is first observed on day 7. It is interesting to see that the elastin is deposited first as wisps. Elastin fibers in canine saphenous vein grafts were also noted to be perpendicular to the longitudinal axis of the vessel and did not form the characteristic lamellae observed in arteries after 3 months' implantation into the femoral artery. 26 Whether the organization of elastin during venous remodeling will mature into the alternating lamellae observed in arteries remains unknown. The deposition of elastin likely confers strength and integrity to the vessel wall, allowing it to endure the hemodynamic environment inherent to arterial flow.
Our studies also documented changes in specific ECM proteins as suggested by the microarray data. Immunohistochemical staining revealed expression of tenascin-C throughout the entire vessel wall during the early stages of venous remodeling. Tenascin-C is an adhesion-modulating glycoprotein of the ECM expressed only in times of inflammation, injury, and tissue remodeling in the adult. 14, 19 It has been shown to block the adhesion of VSMCs to fibronectin and promote their migration. 31 Tenascin-C knockout mice have altered matrix organization as a result of decreased fibronectin deposition in models of wound healing. 32 In addition, tenascin-C is only expressed in patent coronary vein grafts. 33 Our data are in accordance with previous published studies. Tenascin-C is indeed ex-pressed during times of inflammation and tissue remodeling and not expressed when a vessel is in its normal environment. Its early expression correlates with the migration of VSMCs to the intima and the organization of the new ECM during venous remodeling.
Thrombospondin is another adhesion modulating matrix protein that has limited expression in normal vessels. 6 In response to balloon injury of the carotid artery, however, thrombospondin expression leads to increased VSMC proliferation and acts as a potential chemoattractant for their migration to the intima. 34, 35 Mice lacking thrombospondin (1, 2 double knockout) have altered wound healing as evidenced by less dense collagen deposition. 15 Our data reveal the expression of thrombospondin is an important part of the early response to a change in biomechanical environment. Its adhesion-modulating properties likely promote VSMC migration; however, its role in collagen organization during venous remodeling is unknown.
Lysyl oxidase, a copper-dependent monoamine oxidase, is important for structural integrity of the vessel wall. It initiates the cross-linking of collagen and elastin fibers, resulting in stiff collagen fibers and elastin fibers that can stretch and recoil. 16, 36, 37 Although not yet investigated for its role in venous remodeling, its expression is induced by arterial balloon injury. 38 Lysyl oxidase null mice have discontinuous collagen and elastin lamellae leading to diminished resilience and tensile strength of arterial walls, resulting in aneurysms and subsequent death at birth due to rupture. 39, 40 Our data indicate that lysyl oxidase is present during venous remodeling as a new ECM is being synthesized. The expression patterns of lysyl oxidase and elastin suggest components of the ECM cross-link to confer strength and stability to remodeled veins as they are subjected to the hemodynamic forces intrinsic to arterial flow.
Osteopontin is an adhesion modulating glycoprotein of the ECM that promotes VSMC migration. 6 It is interesting to note that osteopontin null mice have arteries with loosely organized collagen fibers as well as an increase in vascular compliance. 17 These mice also demonstrated defects in the organization of collagen in models of wound healing. 20 Osteopontin has several roles during the early stages of venous remodeling. First, as an adhesion modulating protein, it promotes VSMC migration within the vessel wall. Second, it likely confers a decreased vascular compliance to the remodeled vein by promoting organization of collagen fibers. This in turn allows the vessel to withstand the high arterial pressures of its new environment. The exact mechanism by which osteopontin promotes collagen organization remains unknown.
One limitation of this study is that our mouse model of an AVF examines the early stages of venous remodeling, focusing on changes that occur in the vessel wall during the first week after surgery. However, the structural and functional changes that occur during remodeling continue for weeks to months postoperatively. Continuing to investigate our model at later time points will lead to further insight into AVF maturation, which may suggest novel approaches for achieving higher patency rates.
CONCLUSION
The early stages of venous remodeling and subsequent matrix reorganization occur throughout the entire vessel wall in our AVF model. Elastin, tenascin-C, thrombospondin, lysyl oxidase, and osteopontin are expressed resulting in the de novo formation of an ECM scaffold that may be part of a critical adaptive program being evoked to allow the vessel to cope with its new biomechanical environment.
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